NexImmune Presents Initial Data From NEXI-001 Phase 1 Trial For Relapsed/Refractory Post Allo-HSCT AML At 2023 ASCO Meeting
Portfolio Pulse from Benzinga Newsdesk
NexImmune presented initial data from its NEXI-001 Phase 1 trial for relapsed/refractory post allo-HSCT AML at the 2023 ASCO Meeting. The trial showed a favorable safety profile and robust immune response, with one patient achieving no evidence of disease 7 months post-infusion.
June 05, 2023 | 12:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NexImmune's NEXI-001 Phase 1 trial for relapsed/refractory post allo-HSCT AML showed favorable safety profile and robust immune response, potentially benefiting the company's stock.
The positive initial data from the NEXI-001 Phase 1 trial indicates a favorable safety profile and robust immune response, which could lead to increased investor confidence in NexImmune's product pipeline and potential future revenue growth. This may result in a positive short-term impact on the company's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100